Soticlestat long-term OLE data shows sustained seizure reduction in Dravet and LGS

Ovid Therapeutics Inc.

ENDYMION 1 interim analysis: soticlestat generally safe and well tolerated over ~2 years; 78% tolerated 300 mg BID.
Dravet patients: median convulsive seizure reduction -33.7% (wk1-12), -47.8% (wk49-60), -58.2% (wk97-108).
LGS patients: median drop seizure reduction -29.3% (wk1-12), -14.1% (wk49-60), -36.6% (wk97-108).
Post-hoc ELEKTRA analysis: soticlestat showed numerically superior reduction vs placebo across most seizure types.
Ovid maintains significant financial interest in soticlestat (milestones and royalties from Takeda).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.